Literature DB >> 3258514

Verhoeff's query: is vitamin D effective against retinoblastoma?

D M Albert1, A M Saulenas, S M Cohen.   

Abstract

In 1966, Verhoeff suggested that retinoblastomas might be sensitive to vitamin D because they sometimes undergo calcification and spontaneous regression. In recent years, the antineoplastic effect of vitamin D has been established in vitro and in vivo. This study presents evidence that vitamin D2 inhibits the growth of the human retinoblastoma cell line (Y-79) grown in athymic mice. In mice treated with ergocalciferol, the subcutaneous retinoblastomas were smaller and showed increased tumor necrosis and calcification. Unfortunately, the vitamin D caused significant toxic reactions. Further studies that reduce the toxicity of vitamin D will be needed before its use in children with retinoblastomas can be advocated. To our knowledge, this is the first demonstration of the activity of ergocalciferol against a tumor in vivo and it suggests that ergocalciferol or one of its derivatives may be an effective chemotherapeutic agent against retinoblastomas in humans.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3258514     DOI: 10.1001/archopht.1988.01060130582042

Source DB:  PubMed          Journal:  Arch Ophthalmol        ISSN: 0003-9950


  3 in total

1.  1,25-Dihydroxy vitamin D2 induces leukemia cell differentiation.

Authors:  A Yen; J Blue; M Forbes
Journal:  In Vitro Cell Dev Biol       Date:  1991-07

2.  Transgenic models of retinoblastoma: what they tell us about its cause and treatment.

Authors:  D M Albert; A E Griep; P F Lambert; K A Howes; J J Windle; J G Lasudry
Journal:  Trans Am Ophthalmol Soc       Date:  1994

3.  Toxicity and dose-response studies of 1 alpha-hydroxyvitamin D2 in LH beta-Tag transgenic mice.

Authors:  Daniel G Dawson; Joel Gleiser; Michele L Zimbric; Soesiawaiti R Darjatmoko; Jared C Frisbie; Janice M Lokken; Mary J Lindstrom; Isabelle Audo; Stephen A Strugnell; Daniel M Albert
Journal:  Trans Am Ophthalmol Soc       Date:  2002
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.